Cardiology

About 1 in 5 recent novel drug approvals were based on data extrapolated to a broader patient population or in regard to a concomitant drug use, including the controversial aducanumab indication from 2021.

A microsimulation model provides insight into potential years of life expectancy gained by meeting recommended treatment goals for HbA1c, LDL-C, BMI, and blood pressure among adult patients with type 2 diabetes.

Data show 80% of included patients had an increase of more than 20 points in Kansas City Cardiomyopathy Questionnaire summary scores.

Our latest case report features a man in his mid-80s with hypertension, pleural disease, and AF, presenting with 2 days of chest pain radiating to his upper back. Check out the EKG and see if you can determine the correct diagnosis.

The MOSAIC trial provides insight into the effects of a home-based walking exercise program on walkability of patients with peripheral artery disease.

The latest scientific statement from the American Heart Association is aimed at improving the awareness of NAFLD and its associated cardiovascular risk among clinicians as well as optimizing diagnosis and early treatment strategies for patients with NAFLD.

The higher time at BP target ranged from 64% in the triple pill group to 43% in the usual care group

Non-exposure to aspirin in patients with hypertension at risk of ASCVD was associated with decreased risk of cardiovascular events.

Dr. Gregory Weiss, a cardiovascular anesthesiologist, provides perspective into the American College of Cardiology's recently released guidance related to the long-term consequences of COVID-19, which includes information on myocarditis, return to athletics, and more.

Our latest cardiology case report features a man in his mid-60s with a history of lung cancer presenting with progressive worsening SOB for 2 months. Check out the EKG and see if you can determine the proper diagnosis!

No evidence of lower Lp(a)-associated risks in hormone therapy users versus nonusers was observed.

A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.

Dr. Gregory Weiss expounds on recent data indicating routine mammography in postmenopausal women could help identify women at increased risk of cardiovascular disease based on breast arterial calcification.

More research is needed to identify barriers and test interventions to improve hypertension screening and CVD prevention in children with autism

A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.

Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.

Data from POISE-3 presented at ACC.22 detail the effects of tranexamic acid on reducing the risk of major bleeding in patients undergoing noncardiac surgery.

A multi-disciplinary approach could help better manage obesity following bariatric surgery.

Deepak Bhatt, MD, MPH, discusses the results of a prespecified analysis of the COMPLETE detailing a complete revascularization approach to PCI in STEMI resulted in less angina burden than a culprit-lesion-only approach at 3 years.

A study from Intermountain Healthcare provides insight into the tolerability and clinical impact and tolerability of initiating combination therapy with both SGLT2 inhibitors and GLP-1 RAs compared against monotherapy with either agent.

National registry data suggest management and outcomes of ST-elevation myocardial infarction are returning to pre-pandemic levels, though vaccinated patients have fared better in mortality.

Viet Le, PA-C, provides perspective on an ACC.22 study examining long-term risk of MACE based on alcohol consumption and whether or not the patient had a history of statin use.

Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.

Data show omecamtiv mecarbil added to background therapy had no significant improvement regarding exercise capacity.